Rabia Altaf, Asra Iftikhar, Rabia Haq, Bushra Zahoor, Muhammad Zaini Asmawi, Mohamed Khadeer Ahamed Basheer
History, epidemiology, vaccine and transmission of coronavirus disease 2019 (COVID-19): a quick review
Rabia Altaf1*, Asra Iftikhar2, Rabia Haq3, Bushra Zahoor2, Muhammad Zaini Asmawi4, Mohamed Khadeer Ahamed Basheer5
1Department of Pharmacy, The Green International University, Lahore, Pakistan.2Department of Pharmacy, The University of Faisalabad, Punjab, Pakistan.3Department of Family medicine, Agha Khan University Hospital, Karachi, Pakistan.4School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia.5EMAN Research Ltd, Level 3/81 Flushcombe Rd, Blacktown NSW 2148, Australia.
Coronavirus belonging to family Coronaviridae is a large group of viruses causing respiratory and gastrointestinal diseases. The outbreak of 2019-novel coronavirus has created panic in the whole world after being transmitted from Wuhan, China in December 2019. A large number of people are affected throughout the world that forced a solitary situation in the affected areas confining common people to their homes to prevent its spread. Cellular receptors in humans for 2019-novel coronavirus are found to be same as for severe acute respiratory syndrome coronavirus, the first human pandemic of 21st century, however, 2019-novel coronavirus is highly contagious, virulent and mutable than the severe acute respiratory syndrome coronavirus. The most attractive site for vaccine development against 2019-novel coronavirus is the spike glycoprotein which is crucial for receptor binding, membrane fusion via conformational changes, virus internalization, and host tissue tropism or spike inactivation through antibody induced destabilization. First outbreak was in December 2019, later on at the end of 2020, the mortality ratio decreased that created a sigh of temporary relief in the globe. Summer season was considered as one of the sources combating infection and preventing spread of virus. However, for the last few months, suddenly a huge outrage of new variants of coronavirus disease 2019 are capturing attention of the entire population of earth endangering lives of people irrespective of their ages and communities. Researchers must focus on the inventions and discoveries of either preventive or therapeutic medicines that precisely target the spike proteins that enable the severe acute respiratory syndrome coronavirus-2’s entry into a host cell. In this article, we have highlighted various vaccines being approved for emergency use by Federal Investigating Agency to combat the disastrous effects of pandemic on humanity. Mutated variants have created an alarming situation for the health care workers, researchers and scientists to consider the possible mutants and their threat to humanity in the coming years. Further, we have tried to create awareness for developing a global internet community to promote a barrier-free connectivity among all corners of the world to facilitate humanity in case of a category 5 coronavirus disease-hurricane, a term used by researchers for future threats of pandemic.
Pandemic, Severe acute respiratory syndrome coronavirus-2, Social distance, Respiratory illness, Epitopes, S-glycoprotein
History has taken turns changing its course at times due to occasional disease outbreaks ravaging humanity. Although pandemics are no new phenomena to mankind, currently world is facing a major disaster of a pandemic named coronavirus-19 which has affected millions of people round the globe [1]. Clusters of patients with pneumonia of unknown etiology were reported in December 2019 in Wuhan, China which spread to the whole world paralyzing the planet in less than three months creating health, social, economic and financial crisis. The novel virus outraged the classic indicators of reproduction rate and fatality rates of all the previous pandemics of 21st century including influenza, severe acute respiratory syndromecoronavirus (SARS-CoV) and Middle East respiratory syndromecoronavirus (MERS-CoV) [2]. Coronavirus is a large family of virus distributed among humans (human coronavirus, HCoV) and animals. It belongs to family, subfamilyin the order nidovirales comprised of four genera namely alpha-coronavirus, beta-coronavirus, gamma-coronavirus and delta-coronavirus affecting humans, mammals and birds[3–5].Alpha-coronavirus and beta-coronavirus infect mammals and cause respiratory illness [4,6]. Coronavirus possess the largest known viral RNA constituted by ATPase helicase; S-protein (large surface glycoprotein), E-protein (small envelope protein), M-protein (a membrane glycoprotein), N-protein (a neucleoprotein) and an RNA-dependent RNA-polymerase [5]. Approximately one third of common cold infections in humans are the contribution of HCoV-229E, HCoV-NL63, HCoV-OC43 and HCoV-HKU-1 which are four of the identified six HCoVs. Other two are SARS-CoV and MERS-CoV. HCoV-229E and HCoV-NL63 are α-viruses whereas HCoV-OC43 and HCoV-HKU1 are β-viruses [7].
The history of coronavirus started in 1965 through discovery of a virus from nasal discharge of patients with common cold and was named B814 by Tyrrell and Bynoe [8]. Few human strains OC43 and 229E (Hamre’s virus) tended to be epidemic in three decades and infected children mostly. Further three new species of coronavirus capable to attack humans were reported namely human coronavirus NL63 (HCoV-NL63), human coronavirus-HKU1 (HCoV-HKU1) and MERS-CoV[9]. HCoV-NL63 was isolated from an infant with bronchiolitis in 2004 while HCoV-HKU-1 was isolated from a patient with pneumonia in Hong Kong in 2005 [10].
A lethal zoonotic pathogen Middle East respiratory syndrome (MERS) which was diagnosed in Middle East countries especially Saudi Arabia in 2012 infected more than 2,428 individuals [4,5, 11]. The initial symptoms of MERS were mild upper respiratory injury leading to severe acute respiratory syndrome (SARS)and acute lung injury [5]. It may not be highly infectious owing to the fact that it binds to the CD26 receptor mainly expressed in lower bronchi and may need prolonged as well intense exposure to cause respiratory illness [12].
The first human pandemic in 21st century was SARS-CoV that emerged in 2002–2003 in Southern China (Guangdong) and spread worldwidecausing fatalities [4,13].This virus had a link with handling of exotic mammals for human consumption in wet markets of Wuhan, Hubei, a province in China bearing a population of 14 million where live animals were sold [14,15]. It was believed to be spread by international air travel routes infecting 8,098 individuals causing 744 deaths in almost 33 countries of the world with significantly high mortality rate [4,5]. The outbreak was considered the sixth Public Health Emergency of international concern on January 30, 2020[16].
A novel virus which was never previously identified in humans emerged in Wuhan, China in December 2019 named as Wuhan Pneumonia or 2019-nCoV or Wuhan coronavirus or SARS-CoV-2, belonging to genus betacoronavirusand sub-genus[4,5,17,18]. The disease spread is considered to be the third human zoonosis of 21st century[19].
Genus coronavirus are enveloped RNA viruses that may cause disease in animals for example, murine hepatitis virus, avian infectious bronchitis virus etc. and humans as pneumonia in neonates, in immunocompromised patients, military recruits [20].The reservoirs of SARS coronavirus were discovered time to time on basis of evidence and found that initially raccoon dogs, palm civets (in which viral RNA were found), then Rhinolophus bats (source of viral replication) were considered the primary and secondary hosts. The primary host for MERS was found to be camel and its pathogens were not observed in small animals while SARS-CoV and SARS-CoV-2 both by mutation in spike glycoproteins infected animals which may be considered to design suitable model for in-vivo study of pathogen SARS-CoV-2 [5].
The medium-sized RNA viruses with genomic size varying from 26–32 kilobase and 65–125nm in diameter develop in cytoplasm of infected cells of humans. Distribution of cellular receptors for these CoVs are human aminopeptidase-N for group I coronavirus (229E), 9-o-acetylated neuraminic acid for strain organ culture 43 (OC43) and HCoV-HKU1, dipeptidyl-peptidase-4 for MERS-CoV, angiotensin converting enzyme-II for SARS-coronavirus and HCoV-NL63[4, 5,21, 22].
SARS-CoV-2 infected 120,000 individuals in 109 countries with mortality rate 2.9% in such a short duration from its emergence in December 2019 to date. The same angiotensin-converting enzyme-2 (ACE2) cell receptors are being used by SARS-CoV2 with much greater affinity due to mutation in N501T in Spike glycoprotein [5]. The most attractive target for inhibitors and vaccines are spike (S)-proteins of coronavirus comprising of S1 and S2 subunits in each spike monomer providing sunlight based crown like shape to the virus protein and are oriented perpendicular to the cellular membrane [7,23]. The positioning of aromatic and hydrophobic domains to each otherof SARS-CoV was found to be the key role player for its entry into target cells as through receptor binding or membrane fusion [24].
HCoVs gain entry into the host cell via endosomal, non-endosomal and sometimes via combination of both pathways. A conformational change triggered in the S protein by the interaction between the S1 domain and its cognate receptor promotes the membrane fusion between the viral and cell membranes through S2 domain. These pathways are supported by certain factors as low pH in cellular environment, certain proteases as cathepsin-L, transmembrane protease serine 2 and airway trypsin like proteases [22]. HCoVs induce apoptosis in intestinal mucosal cells, kidney tubular cells, neuronal dendritic cells and immune cells suppressing the host innate and adaptive immune responses [22]. SARS-CoV is highly contagious which crossed the species barrier and was enabled for human to human transmission [25].It may get transmitted via droplets in secretions as feces, urine, aerosols or respiratory secretions while retaining its infectivity for 7 days[13].
The RNA-recombination in S-glycoprotein among the existing coronaviruses caused the emergence of novel coronaviruses, e.g.2019-nCoV from SARS-CoV, which had an outbreak as a fatal pandemic spreading from Wuhan, Hubei province of China to almost whole world. It was later named as SARS-CoV-2 [6,11,18]. Both SARS-CoV and SARS-CoV-2 share their gene content with each other as proteases (papain-like protease and 3-C like protease), S-glycoprotein and the RNA-dependent RNA polymerase (Nsp12) [26]. According to the serology and phylogeny, HCoV is classified in four genera. Please refer toFigure 1 for the illustration depicting the classification tree of HCoV. Table 1 shows the chronology and pandemic details of the different types of HCoVs[27].
The enhancement of cross-species transmission in virus might be due to homologous recombination at S-glycoprotein of receptor binding domain (RBD) region. This region is considered crucial site for receptor binding, membrane fusion via conformational changes, virus internalization, host tissue tropism or spike inactivation through antibody induced destabilization [4,6,17,21]. SARS-CoV-2 RBD recognizes ACE2 receptors better than SARS-CoV RBD according to Jian, since SARS-CoV-2-receptor binding motifhas evolved strategies to neutralize the charges on the lysine residues which is the key factor to facilitate the binding of coronavirus RBD to ACE2 [21,23,26]. COVID-19 binds to ACE2 that is expressed largely on the surface of alveolar cells in lungs. The adults and especially the adult men have higher plasma concentration of circulating ACE2, so the elderly, health care workers, and anyone with underlying health conditions are at higher risk to get infected from the disease [28].
Several novel cytotoxic T-lymphocytes epitopes and vectors were found on SARS-CoV-2 which suggested the development of peptide based vaccine to prevent 2019-nCoV infection since it is closely related to predecessor SARS-CoV [6,29, 30]. Remdesivir was approved initially for emergency treatment of SARS-CoV-2 since it inhibits the RNA-dependent RNA polymerase of coronavirus which is being used for transcription of its genes and replication of its genome [6,31]. Chloroquine has been demonstrated to act as an immunomodulator to enhance the antiviral effect in vivo as well as interferes with ACE2 by affecting at entry and post entry stages of 2019-nCoVwhich was later not found as much effective [3]. An anti-neoplastic carmofur has been found to inhibit main proteasethereby inhibiting viral replication in cells giving way to development of new antiviral treatment of COVID-19 [6,32]. Immune enhancers, Chinese herbs as well as intravenous gamma globulins were found to improve the symptoms of corona virus.
Different experiments are being carried out in the whole world in different laboratories to search medicinal plants containing anti-viral phytochemicals that may inhibit the virus replication and to develop novel anti-COVID-19 therapeutic agents and vaccines to prevent the attack of viruses [33–35]. To prioritize the high-risk patients for COVID-19, an interpretable mortality prediction model was being developed in China which uses lactic dehydrogenase as a biomarker tool [6,36]. Dexamethasone, a glucocorticoid was used in few cases to reduce the death of patients of COVID-19 by one third [37]. It is economical drug available throughout the world previously being used as an anti-inflammatory as well as anticancer. Convalescent plasma technique to boost up the immune system of patients of COVID-19 has been used to fight off against virus with the help of antibodies in few trials during collaborative studies of different universities [38].
The clinical trials of newly developed drugs and vaccines are carried out. These clinical trials are comprised of three phases, the phase-1 trials and phase-2 trials and phase-3 trials [39]. The trials carried out on animals provide the data for phase-1 trials. Phase-1 trials are simply performed to establish the safety. The effect of dose on different biomarker correlates with protection is examined in phase-2 trials to establish the desired protective efficacy.
Ultimately phase-3 trials critically evaluate the vaccine to achieve clinical end point, in this case, that may be the protection against COVID-19 from SARS-CoV-2 exposure [40]. Since the vaccine is a biological preparation to protect humans from viral and bacterial infections, it is the crucial step taken by the world’s scientists to develop vaccine against COVID-19 to protect this world and next generations from the lethal viral attack. The vaccine development technology has undergone great evolution by formulating cell-culture-based vaccines, licensed vector vaccines, recombinant protein vaccines, DNA-vaccines and RNA-vaccine candidates in last decade. The key target sites for vaccine development are enlisted comprising spike proteins, spike RBD, spike N-terminal domain, M-protein, E-protein and N-protein etc. [41, 42,43]. After passing through the clinical trial phases, a number of candidate vaccines are brought for further considerations.
Food and Drug Administration (FDA)-approved inactivated viral vaccines by Beijing Institute of Biological Products Company and inactivated SARS-CoV-2 vaccine by Sinovac, a Chinese company.

Figure 1 Classification of human coronaviruses. HCoV, human coronavirus.

Table 1 Comparison of different types of human coronaviruses
HCoV, human coronavirus.
Protein, nucleic acid base vaccines and virus like particles are used as SARS-CoV-2 nanoparticulate subunit vaccine formulations. The subunit formulations often require co-administration of an adjuvant as aluminum salts(alum), combination of monophosphoryl lipid Aand alum.
●A subunit vaccine with Trimer-Tag technology with a stabilized spike protein timer by Clover Biopharmaceuticals Inc. in Australia.
●A vaccine candidate using spike protein trimer with MF95 adjuvant by University of Queensland [44].
●Vaccine candidate using RBD-dimer by Anhui Zhifei Longcom Biopharmaceutical and the Institute of Microbiology at the Chinese Academy of Sciences.
●Vaccine Pty Ltd with Medytox using recombinant spike protein as antigen and Advax as an adjuvant. The recombinant protein vaccine is considered more preferable than the RNA and viral vector vaccines due to its potent and effective nature [45].
●Vaccine candidate of a spike protein with double prolinesubstitution by Medigen Vaccine Biologics corporation, the National Institute of Allergy and Infectious Disease, and Dynavax.
The subunit vaccine candidates to design a vaccine against MERS-CoV have used membrane protein and spike glycoproteins that opens the window for recommendation of these vaccines against MERS-CoV as well as current pandemic COVID-19 [46]. ChAdOx1 nCoV-19, a viral vector vaccine has been given trial in four randomized clinical trials to assess its safety and efficacy against the novel coronavirus in Brazil, Britain and South Africa with quite positive outcome forming a basis for development of new vaccines against COVID-19 [47]. The new variants of COVID-19 have attacked children under ten years of age too so further study is required to evaluate the potential risk factors for the development of critical symptoms of COVID-19 in children[48].
Some of the vaccines being used currently after clinical trials in a number of countries in different parts of the world are:
●Pfizer/BioNtech (BNT162b2).An emergency use authorization for the vaccine was issued by FDA on December 11, 2020 for a lipid nanoparticle-formulated, modified RNA particle encoding SARS-CoV-2 full length spike, BNT162b2. Almost at 150 sites worldwide, 43,448 patients were randomized in a 1:1 distribution showing 95% efficacy 49.
●Moderna (mRNA-1273). Preliminary results showed the effectiveness of Moderna to be 94.1% against SARS-CoV-2. An emergency use authorizationwas issued by FDA on December 18, 2020 for Moderna to be given 0.5mL, 2doses-28 days apart. It’s a lipid nanoparticle containing mRNA encoding for spike proteins once absorbed results in immune response development by spike protein expression.
●Novavax (NVX-CoV2373) (virus like particle vaccine). An adjuvant is added to nanoparticles coated with synthetic spike proteins, which showed an efficacy of 89% (US/UK strain) with a dose regimen of 2 doses-21 days apart.
●Sinopharm (BBIBP-CorV). Keeping all the proteins intact, the SARS-CoV-2 is chemically inactivated by beta-propiolactone, showed efficacy of 79% with 2 doses-3 weeks apart.
●Sputnik V (Gamaleya) (Sputnik V/Gam-Covid-Vac). Immune response is produced by spike proteins expressed by infected cells showed 91% efficacy by 0.5mL given in 2 doses-28 days apart.
●Oxford/Astrazeneca (ChAdOx1/AZD1222) (Covidshield). Its also a viral vector vaccine that leads to immune response by spike proteins expression showing efficacy of 82% with 2 doses-12 weeks apart.
Factors that determine vaccines to be incorporated globally are: (a) complexity to find most effective candidate; (b) storage requirements; as refrigerated versus frozen; (c) requirement of a single or more injection for optimal immunity.
The decision to get vaccinated or not is affected by a number of factors around the world, as social norms, the parent level of education, the socio-demographic context and the religious beliefs [50]. Approximately more than 180 vaccines are in production phase but still a conflict is there among the world’s population for who should receive the vaccine first. Young people must receive it initially to face the possible side-effects for possessing better immunity than older ones, is the high talk now-a-days. A single-dose vaccination strategy is considered appropriate for high-exposure, low-risk individuals while two-dose regimen is considered suitable for the high-risk populations and for older adults. An increasing interest and trend in single-dose strategies has become the top trend to shift as many people as possible to vaccination. Relaxed prevention, possibility of reinfection, virus mutation and vaccination delays are a combination of factors that may lead to long-haul COVID or long-COVID, literally a category 5 “COVID-hurricane”, that may cause infections that can linger for months [51].
A trustworthy continuous internet facility with strong end-to-end encryption is becoming the need of era in near future. In such a pandemic crisis that has implemented a long term social distance in general, current internet facility has made people to work from home, to gain uninterrupted online education, exchange of emotional values among isolated family members during quarantine times. Still 50% of the world’s population could not have access to internet in remote and rural areas. Community-driven connectivity must be made barrier-free by lawmakers and regulators to ensure easy access of each and every community to uninterrupted internet as the best means of communication [52].
The novel COVID-19 is found to be able to spread human to human by exposure to cough, sneeze, droplets, aerosols inhaled by mouth or nose, contact of subject with object infected with virus and transmission of virus to nose or mouth of subject [5,6,14,53]. In very few cases, it may have been the digestive route where ACE2 was considered expressive in ileum and colon[53]. Other routes of transmission as through breast milk, sweat, semen or fecal etc. are still under review in different areas of the world to gain knowledge which may help to prepare its vaccine [1].
Another route of transmission of coronavirus is considered to be through the intermediate hosts, that are through the animals. Undercooked meat of animals, urine or milk consumption or through unknown wild animals are considered for a detailed knowhow.
Since the deadly virus is considered to be viable for hours in the air and for days on surfaces of plastic, copper, steel and cardboard, it may be transmitted through contaminated surfaces and aerosols.
The stability and transmission rate of SARS-CoV-2 varies with difference in environmental parameters as humidity, temperature and sunlight. The spread was recorded least in African countries with high temperature and highest in cold areas of the world in winter season especially when respiratory symptoms worsen.
The only reported evidence of coronavirus transmission from human to animal was in Bronx Zoo of USA, where the virus was transferred from asymptomatic zookeeper to tiger, which gives an alarming situation. The issue is still under consideration [16].
The symptoms of COVID-19 range from asymptomatic conditions to flu, sneezing cough, myalgia, fever, pneumonia, complicated dyspnea and more severe symptoms includeacute lung injury, shock and acute kidney injury [54]. SARS-CoV-2 might target all organs including lungs [55]. Since many pathogens are present in saliva and nasopharyngeal secretions, any type of dental procedure may be considered an easy route of transmission of airborne contamination [56]. Real time PCRmay be performed for the diagnosis of nucleic acid of SARS-CoV-2 in the samples of throat swab, sputum and secretions of lower respiratory tract [6,53]. To overcome the accessibility and availability of real time PCR, various serological tests including ELISA, immunoglobulin M, immunoglobulinG, computed tomography and chromatographic tests are being used for qualitative detection of SARS-CoV-2 [57].
Mean incubation period of SARS-CoV-2 is suggested as 3–6 days with the interval of onset of symptoms and appearance of acute respiratory distress syndrome of almost 6–7 days suggesting the consideration of 14 days for medical observation from initial exposure [3].Extreme rise in inflammatory cytokines as tumor necrosis factor alpha, and interleukins cause progression of pneumonia at the end of 1st week causing death in some cases especially in elderly although all ages are susceptible [57]. Some cohort studies reported gastrointestinal symptoms as anorexia, nausea, vomiting, diarrhea etc., whereby live 2019-CoV were found in stool specimens, patients’s with neurological manifestations including headache, dizziness, ischemic and hemorrhagic strokes, olfactory and taste disorders as well as immune system disorders [26,58].
World Health Organization gave a detailed guideline to use proper hygienic measures to prevent the spread of disease from person to person and from infected objects to subjects [59]. These guidelines includedwashing hands properly with water and soap, using sanitizers (at least with 60% alcohol) whenever touching any object, use of certified respirators as non-oil mask with 95% efficiency (N95) and filtering face piece 2 (FFP2) while performing aerosol procedures, covering face especially nose and mouth with face masks to avoid entry of airborne droplets through nose or mouth when in social contact, using flexed elbow while coughing or sneezing, avoid touching nose, eyes or mouth frequently, to stay at home and avoid any gatherings as well as observe social distance to prevent spread of disease from person to person [6,54,60]. The comparison of mask-off settings and mask-on settings revealed a great rate of spread of the COVID-19 clusters from one person to other. The extent of transmission was mitigated by universal masking phenomenon in the communities. It is still advisable wear the facial masks to avoid the transmission of virus from one person to another. Personal protection with the use of reusable masks, gowns and gloves is highly encouraged to combat the emerging infectious disease[61].
The unpredictable challenges are being faced by both patients and specialists since the emergence of new variants of COVID-19, especially by the patients with other pre-existing diseases as congenital heart failure or asthma [62]. A two-fold threat to human health may occur by the attack of novel viral pathogens in individuals with decreased host immunity due to micronutrient deficiency. Certain micronutrients as zinc, selenium, iodide, copper, iron and vitamins as vitamin A, B, C, D and E present a supporting role on the host immune response to viral infection. Their deficiency may become opportunistic approach for viral mutation through host cell permissiveness [63]. The role of host immunity and micronutrients to resist the attack by infectious viral pathogens must be investigated more to get long-term benefits against future viral outbreaks [64]. Special precautionary measures as avoiding crowd, maintaining social distance, usage of N95 respirators, protective suits and goggles, proper nutrition etc. must be adapted by government and people themselves to avoid the spread of disease.
After a dynamic study of transmission of the disease from its origin to the whole world irrespective of climate, a number of articles came in press determining the statistical analysis of transmission rate and strategies to assess its clinical severity including number of infected persons leaving the Wuhan state via different departure routes, number of patients infected per day, time of onset of disease to death of patients, the transmission route of disease from person to person or object to subject and the symptomatic appearance of disease etc. [65]. Breast feeding mothers and pregnant ladies require precautions to avoid transmission of virus to neonates since they remain at high risk for development of severe respiratory complications A study was carried out on almost 31 expecting mothers of which 2 died due to respiratory complications after delivery although none of them gave any evidence to transfer the disease to neonates but still they claimed the transfer of droplets while feeding the babies [66]. Vaccination transfers the immunity from mother to infant as per reference to our history of vaccination for pertussis and tetanus provides a great insight to adapt a vital public health measure to reduce preventable mortality and morbidity for the mother, fetus and infant [67]. While developing a vaccine, a broad spectrum cross protection approach must be considered to develop a vaccine that may be applied to exert its protective effects in case of similar viral diseases in humans or animals in future [12].
The pandemic has spread throughout the world in no time infecting almost 145 million people round the globe. Many have been recovered by keeping themselves socially distant, in quarantine. Half of the countries have been through severe lock down to prevent the spread of disease through borders. Few are back to their normal living and few are still suffering that has created a huge economic crisis leaving a large population unemployed. A huge responsibility falls on medical personnel, health care professionals, doctors, pharmacists, scientists to make collaborative efforts to develop vaccine for 2019-CoV to counteract its hazardous effects in coming generations. Although vaccine development is a need of the day but following all the procedures for vaccine development including clinical trials, it would also be quite time demanding to let each and every human on globe to be vaccinated for the novel coronavirus [68]. Meanwhile, implementation of specific preventive measures, provision of quarantine facilities worldwide, maintenance of social distance, campaigns for awareness of hygiene as well as the knowledge of symptoms of the disease to prevent its spread are few of the unavoidable liabilities on the government bodies of each country to combat aftereffects of the pandemic. At the same time, a serious focus is to be advocated for people to stay mentally healthy and augment the focus on resilience and on strategies to improve it [69].
1. Haleem A, Javaid M. Effects of COVID-19 pandemic in daily life.. 2020; 10(2):78–79. Available: 10.1016/j.cmrp.2020.03. 011; https://doi.org/10.1016/j.cmrp.2020.03. 011
2. Peterson E, Koopmans M, Go U, et al. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics.. 2020;20(9):238–244. Available: 10.1016/S1473-3099(20) 30484-9; https://doi.org/10.1016/S1473-3099 (20)30484-9
3. Xue L, Li J, Wei L, Ma C. A quick look at the latest developments in the COVID-19 pandemic.. 2020;48(9):1–8. Available: 10.1016/j.cub.2015.04.020; https://doi.org/10.1177/0300060520943802
4. Bhattacharya S, Sharma P, Mathur H, et al. Recent apprise on coronavirus and its terrible insinuations.. 2020;31(2):1–7. Available: 10.1007/s13337-020-00582-2; https:// dx.doi.org/10.1007/s13337-020-00582-2
5. Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: origin, transmission, and characteristics of human coronaviruses.. 2020;24(1):91–98. Available: 10.1016/j.jare.2020.03.005; https://dx. doi.org/10.1016/j.jare.2020.03.005
6. Kumar S, Maurya VK, Prasad AK, Bhatt MLB, Saxena SK. Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV).. 2020;31(1):13–21. Available:10.1007/s13337-020-00571-5;https:// dx.doi.org/10.1007/s13337-020-00571-5
7. Parameshwar K, Pamu S, Sandeep K, Suresh C. A review novel coronavirus.. 2020;13(4)12–17. Available: 10.22159/ ajpcr.2020.v13i4.36982; https://dx.doi.org/10.221 59/ajpcr.2020.v13i4.36982
8. Kahn JS, McIntosh K. History and recent advances in coronavirus discovery.. 2005;24(11 Suppl):S223–227. Available: 10.1097/01.inf.0000188166.17324.60; https://dx. doi.org/10.1097/01.inf.0000188166.17324.60
9. Woo PC, Lau SK, Chu CM, et al. Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia.. 2005;79(2):884–895. Available: 10.1128/JVI.79.2.884-895.2005; https: //dx.doi.org/10.1128/JVI.79.2.884-895.2005
10. Jonsdottir HR, Dijkman R. Coronaviruses and the human airway: a universal system for virus-host interaction studies.. 2016;13:24. Available: 10.1186/s12985-016-0479-5; https://doi.org/ 10.1186/s12985-016-0479-5
11. Iwasawa T, Sato M, Yamaya T, et al. Ultra-high-resolution computed tomography can demonstrate alveolar collapse in novel coronavirus (COVID-19) pneumonia.. 2020;38(5):394–398. Available: 10.1007/s11604-020-00956-y; https://doi.org/ 10.1007/s11604-020-00956-y
12. Contini C, Di Nuzzo M, Barp N, et al. The novel zoonotic COVID-19 pandemic: an expected global health concern.. 2020;14(3):254–264. Available: 10.3855/jidc. 12671; https://doi.org/10.3855/jidc.12671
13. Franks TJG, Jeffrey R. Coronavirus. In: Fraire AE, Woda BA, Welsh RM, Kradin RL. ed.. Springer-Verlag Berlin Heidelberg;2014:Chapter 13:109–116.
14. Zhu H, Wei L, Niu P. The novel coronavirus outbreak in Wuhan, China.. 2020;5:6. Available: 10.1186/s41256 -020-00135-6; https://doi.org/10.1186/s41256-020-00135-6
15. Institute of Medicine (US) Forum on Microbial Threats.. Knobler S, Mahmoud A, Lemon S, Mack A, Sivitz L, Oberholtzer K, ed. Washington: National Academies Press;2004.
16. Rabaan AA, Al-Ahmed SH, Muhammad J, et al. Role of inflammatory cytokines in COVID-19 patients: A review on molecular mechanisms, immune functions, immunopathology and immunomodulatory drugs to counter cytokines storm.2021;9(5):436. Available: 10.3390vaccines9050436;https://doi.org/10.3390vaccines9050436
17. Wang C, Li W, Drabek D, et al. A human monoclonal antibody blocking SARS-CoV-2 infection.. 2020;11(1):2251. Available: 10.1038/s41467-020-16256-y; https:// dx.doi.org/10.1038/s41467-020-16256-y
18. Boulos MNK, Geraghty EM. Geographical tracking and mapping of coronavirus disease COVID-19/severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic and associated events around the world: how 21st century GIS technologies are supporting the global fight against outbreaks and epidemics.. 2020;19(1):8. Available: 10.1186/s12942-020-00202-8; https://doi.org/ 10.1186/s12942-020-00202-8
19. AsraniP, HasanGM, SohalSS, HassanMI. Molecular basis of pathogenesis of coronaviruses: a comparative genomics approach to planetary health to prevent zoonotic outbreaks in the 21st century.. 2020;24(11):634–644. Available: 10.1089/omi.2020.0131; https://doi.org/10.10 89/omi.2020.0131
20. Peiris JS, Lai ST, Poon LL, et al. Coronavirus as a possible cause of severe acute respiratory syndrome.. 2003;361(9366):1319–1325. Available: 10.1016/s0140-6736(03)13077-2; https: //dx.doi.org/10.1016/s0140-6736(03)13077-2
21. Shang J, Ye G, Shi K, et al. Structural basis of receptor recognition by SARS-CoV-2.. 2020;581(7807):221–224. Available: 10.1038/s41 586-020-2179-y; https://doi.org/10.1038/s415 86-020-2179-y
22. Lim YX, Ng YL, Tam JP, Liu DX. Human coronaviruses: areview of virus-host interactions.. 2016;4(3):26. Available: 10.3390/ diseases4030026; https://doi.org/10.3390/ diseases4030026
23. Lan J, Ge J, Yu J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor.. 2020;581(7807):215–220. Available: 10.1038/ s41586-020-2180-5; https://doi.org/10.1038/s 41586-020-2180-5
24. Corver J, Broer R, van Kasteren P, Spaan W. Mutagenesis of the transmembrane domain of the SARS coronavirus spike glycoprotein: refinement of the requirements for SARS coronavirus cell entry.. 2009;6:230. Available: 10.1186/1743-422X-6-230; https://doi.org/10.1186/1743-422X-6-230
25. Antia R, Regoes RR, Koella JC, Bergstrom CT. The role of evolution in the emergence of infectious diseases.. 2003;426(6967):658–661. Available: 10.1038/nature02104; https:// dx.doi.org/10.1038/nature02104
26. Cevik M, Bamford CGG, Ho A. COVID-19 pandemic-a focused review for clinicians.. 2020;26(7):842–847. Available: 10.1016/j.cmi.2020.04.023; https://doi.org/10. 1016/j.cmi.2020.04.023
27. Ye ZW, Yuan S, Yuen KS, Fung SY, Chan CP, Jin DY. Zoonotic origins of human coronaviruses.. 2020;16(10):1686–1697. Available: 10.7150/ijbs.45472; https://doi.org/10.7150/ ijbs.45472
28. Gallego P, Ruperti-Repilado FJ, Schwerzmann M. Adults with congenital heart disease during the coronavirus disease 2019 (COVID-19) pandemic: are they at risk?. 2020;73(10):795–798. Available: 10.1016/j.rec.20 20.06.016; https://doi.org/10.1016/j.rec.2020. 06.016
29. Sarkar B, Ullah MA, Johora FT, Taniya MA, Araf Y. Immunoinformatics-guided designing of epitope-based subunit vaccines against the SARS Coronavirus-2 (SARS-CoV-2).. 2020;225(3):151955. Available: 10.1016/j.imbio. 2020.151955; https://doi.org/10.1016/j.imbio. 2020.151955
30. Lim HX, Lim J, Jazayeri SD, Poppema S, Poh CL. Development of multi-epitope peptide-based vaccines against SARS-CoV-2..2020;44(1):18–30. Available: 10.1016/j.bj.2020. 09.005; https://doi.org/10.1016/j.bj.2020.09. 005
31. Hillen HS, Kokic G, Farnung L, Dienemann C, Tegunov D, Cramer P. Structure of replicating SARS-CoV-2 polymerase.. 2020;584(7819):154–156. Available: 10.1038/s41586 -020-2368-8; https://doi.org/10.1038/s41586- 020-2368-8
32. Jin Z, Zhao Y, Sun Y, et al. Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur.. 2020;27(6):529–532. Available: 10.1038/s41594- 020-0440-6; https://doi.org/10.1038/s41594- 020-0440-6
33. Qamar MT, Alqahtani SM, Alamri MA, Chen LL. Structural basis of SARS-CoV-2 3CL(pro) and anti-COVID-19 drug discovery from medicinal plants.. 2020;10(4):313–319. Available: 10.1016/j.jpha.2020.03.009; https://dx. doi.org/10.1016/j.jpha.2020.03.009
34. Xu B, Gutierrez B, Mekaru S, et al. Epidemiological data from the COVID-19 outbreak, real-time case information.. 2020;7(1):106. Available: 10.1038/s41597-020- 0448-0; https://doi.org/10.1038/s41597-020-0 448-0
35. AnandAV, Balamuralikrishnan B, Kaviya M, et al. Medicinal plants, phytochemicals, and herbs to combat viral pathogens including SARS-CoV-2.. 2021;26(6):1775. Available: 10.3390/ molecules26061775; https://doi.org/10.3390/ molecules26061775
36. Yan L, Zhang HT, Goncalves J, et al. An interpretable mortality prediction model for COVID-19 patients.. 2020;2(5):283–288. Available: 10.1038/s42256- 020-0180-7; https://doi.org/10.1038/s42256- 020-0180-7
37. The RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with Covid-19.. 2021;384(8):693–704. Available: 10.1056/NEJM oa2021436 https://doi.org/10.1056/NEJMoa 2021436
38. Bartsch SM, O’Shea KJ, Wedlock PT,et al. The benefits of vaccinating with the first available COVID-19 coronavirus vaccine.. 2021;60(5):605–613. Available: 10.1016/j.amepre. 2021.01.001; https://doi.org/10.1016/j.amepre. 2021.01.001
39. Rab S, Afjal, Javaid M, Haleem A, Vaishya R. An update on the global vaccine development for coronavirus.2020;14(6):2053–2055. Available: 10.1016/j.dsx. 2020.10.023; https://doi.org/10.1016/j.dsx. 2020.10.023
40. Batty CJ, Heise MT, Bachelder EM, Ainslie KM. Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection.. 2021;169:168–189. Available: 10.1016/j.addr.2020.12.006; https://doi.org/10.1016/j.addr.2020.12.006
41. Kaur N, Singh R, Dar Z, Bijarnia RK, Dhingra N, Kaur T. Genetic comparison among various coronavirus strains for the identification of potential vaccine targets of SARS-CoV2.2020;89:104490. Available: 10.1016/j.meegid.2020.104490; https://doi.org/ 10.1016/j.meegid.2020.104490
42. Ita K. Coronavirus disease (COVID-19): current status and prospects for drug and vaccine development.. 2020;52(1):15–24. Available: 10.1016/j.arcmed.2020.09.010; https:// dx.doi.org/10.1016/j.arcmed.2020.09.010
43. Jacob JJ, Vasudevan K, Veeraraghavan B, Iyadurai R, Gunasekaran K. Genomic evolution of severe acute respiratory syndrome coronavirus 2 in India and vaccine impact.. 2020;38(2):210–212. Available: 10.4103/ijmm.IJMM_20_303; https://doi.org/ 10.4103/ijmm.IJMM_20_303
44. Gupta P. A review: epidemiology, pathogenesis and prospect in developing vaccines for novel coronavirus (COVID-19).. 2020;68(1):92–98. Available: 10.1016/j.ijtb.2020. 09.021; https://doi.org/10.1016/j.ijtb.2020. 09.021
45. Almond J, Hacker J, Harwood C, et al.Development of vaccines at the time of COVID-19.. 2020;1(1):uqaa003.Available: 10.1093/femsml/uqaa003; https://dx. doi.org/10.1093/femsml/uqaa003.
46. Kyriakidis NC, López-Cortés A, González EV, Grimaldos AB, Prado EO. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates.. 2021;6(1):1–17. Available: 10.1038/s41541-021-00292-w; https:// dx.doi.org/10.1038/s41541-021-00292-w
47. Voysey M, Clemens SAC, Madhi SA, et al.Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.. 2021;397(10269):99–111. Available: 10.1016/S 0140-6736(20)32661-1; https://doi.org/10.10 16/S0140-6736(20)32661-1
48. Tsabouri S, Makis A,Kosmeri C, Siomou E. Risk factors for severity in children with coronavirus disease 2019: acomprehensive literature review.. 2021;68(1):321–338. Available: 10.1016/j.pcl.2020.07.014; https://dx. doi.org/10.1016/j.pcl.2020.07.014
49. Zhu N, Zhang D, Wang W, Li X, et al. A novel coronavirus from patients with pneumonia in China, 2019.. 2020;382(8):727–733. Available: 10.1056/NEJMoa2001017; https://doi.org/10.1056/NEJMoa2001017
50. Baumgaertner B, Carlisle JE, Justwan F. The influence of political ideology and trust on willingness to vaccinate..2018;13(1):e0191728. Available: 10.1371/journal.pone.01917 28; https://doi.org/10.1371/journal.pone.0191728
51. Syrek R. Trending clinical topic: single-dose vaccination. https://reference.medscape.com/viewarticle/946524. Published March 05, 2021. Accessed March05, 2021.
52. Abuhammad S.Barriers to distance learning during the COVID-19 outbreak: a qualitative review from parent’s perspective.. 2020;6(11):e05482. Available: 10.1016/j.heliyon. 2020.e05482; https://doi.org/10.1016/j.heliyon. 2020.e05482
53. Adhikari SP, Meng S, Wu YJ, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review.. 2020;9(1):29. Available: 10.1186/s40249-020-00646-x; https:// dx.doi.org/10.1186/s40249-020-00646-x
54. Singhal T. A review of coronavirus disease-2019 (COVID-19).. 2020;87(4):281–286. Available: 10.1007/s12098-020-03263-6; https://doi.org/10.1007/s12098-020-03263-6
55. Borsanahan SB, Jonkman AH, Kugler MC, Munger JS, Kaufman DA. COVID-19 and respiratory system disorders.2020;40(11):2586–2597. Available: 10.1161/ATVBAHA.120.314515; https://dx.doi. org/10.1161/ATVBAHA.120.314515
56. Ali SZU, Muhammad A. Transmission routes and infection control of novel coronavirus-2019 in dental clinics – areview.. 2020;1(9):65–72. Available: 10.1177/03000 60520943802; https://doi.org/10.1177/03000 60520943802
57. Jain N, Choudhury A, Sharma J, Kumar V, De D, Tiwari R. A review of novel coronavirus infection (coronavirus disease-19).2020;5(1):22. Available: 10.4103/GJTM.GJTM _24_20; https://doi.org/10.4103/GJTM.GJTM _24_20
58. Wolfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019.. 2020;581(7809):465–469. Available: 10.1038/s41586-020-2196-x; https://doi.org/10.1038/s41586-020-2196-x
59. Kumar D, Malviya R, Sharma PK. Coronavirus: areview of COVID-19.. 2020;4(1):8–25. Available: 10.14744/ejmo.2020. 90853; https://doi.org/10.14744/ejmo.2020. 90853
60. Carbone M, Lednicky J, Xiao SY, et al. Coronavirus 2019 infectious disease epidemic: where we are, what can be done and hope for..2021;16(4):546–571. Available: 10.1016/j.jtho.2020.12.014; https://doi.org/10. 1016/j.jtho.2020.12.014
61. Cheng VCC, Wong SC, Chuang VWM, et al. The role of community-wide wearing of face mask for control of coronavirus disease 2019 (COVID-19) epidemic due to SARS-CoV-2.. 2020;81(1):107–114. Available: 10.1016/j.jinf. 2020.04.024; https://doi.org/10.1016/j.jinf. 2020.04.024
62. Bansal M.Cardiovascular disease and COVID-19.. 2020;14(3):247–250. Available: 10.1016/j.dsx.2020.03.013; https://dx. doi.org/10.1016/j.dsx.2020.03.013
63. Gombart AF, Pierre A, Maggini S.A review of micronutrients and the immune system-working in harmony to reduce the risk of infection..2020;12(1):236. Available: 10.3390/ nu12010236; https://doi.org/10.3390/nu120102 36
64. Katona P. The interaction between nutrition and infection..2008;46(10):1582–1588. Available: 10.1086/587658; https://dx. doi.org/10.1086/587658
65. Wu JT, Leung K, Bushman M, et al. Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China.. 2020;26(4):506–510. Available: 10.1038/s41591 -020-0822-7; https://doi.org/10.1038/s41591-0 20-0822-7
66. Zarchi MK, Neamatzadeh H, Dastgheib SA, et al. Vertical transmission of coronavirus disease 19 (COVID-19) from infected pregnant mothers to neonates: areview.. 2020;39(3):246–250. Available: 10.1080/15513 815.2020.1747120; https://doi.org/10.1080/155 13815.2020.1747120
67. Elahi S, Buchanan RM, Babiuk LA, Gerdts V. Maternal immunity provides protection against pertussis in newborn piglets.. 2006;74(5):2619–2627. Available: 10.1128/IAI. 74.5.2619-2627.2006; https://doi.org/10.1128/ IAI.74.5.2619-2627.2006
68. Helmy Y. No scientific clinical evidence for long term safety of newly evolved COVID-19 vaccines: review and meta-analysis..2020;1(4):106–110. Available: 10.21608/aimj. 2020.55247.1382; https://doi.org/10.21608/ aimj.2020.55247.1382
thanks Anil Batta, Kanu Megha,Chinyere Mma Okoh, Yang Liu for the contribution to the peer review of this paper.
:
SARS, severe acute respiratory syndrome; MERS, Middle East respiratory syndrome; ACE2, angiotensin-converting enzyme-2; RBD, receptor binding domain.
:
The authors declare that they have no conflict of interest.
:
We would like to acknowledge the support of the Green International University, however no funding support has been provided by any organization.
:
Altaf R, Iftikhar A, Haq R, Zahoor B, Asmawi MZ, Basheer MKA.History, epidemiology, vaccine and transmission of coronavirus disease 2019 (COVID-19): a quick review.. 2021;4(3):19. doi: 10.53388/life2021-0406-301.
:Shan-Shan Lin.
:06 April 2021,
05 June 2021,
:09 July 2021
© 2021 By Authors. Published by TMR Publishing Group Limited. This is an open access article under the CC-BY license (http://creativecommons.org/licenses/BY/4.0/).
Rabia Altaf. The Green International University,Bhobattian Chowk,Raiwind Road,Lahore,Pakistan; E-mail:rabia.ihtisham@gmail.com.